CellaVision Q3’20: First comments
Redeye’s first comments on CellaVision’s report for the Q3 report showed sales considerably lower than expected at SEK 88m vs. our SEK 117m. The gross margin was also lower at 65% compared with the 68% expected. Even though the deviation was a bit larger than we had hoped for, we still have a positive long-term view, and the clearance of DC-1 in the US is good news for the long term prospects.
Any significant dips can provide good opportunities to buy the share.